TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12972476

Group type: EXPERIMENTAL
Intervention: IV ibandronate 2 mg
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: IV ibandronate 1 mg
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: IV ibandronate 0.5 mg
Number of subjects: 629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: All doses of ibandronate
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: IV ibandronate
Number of subjects: 629
Study: 10712859

Group type: EXPERIMENTAL
Intervention: Delta4, 16‐androstadien‐3‐one
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1,3,5(10)16‐estratetraen‐3‐ol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clove oil carrier solution
Number of subjects: 0
Study: 8665577

Group type: EXPERIMENTAL
Intervention: MK-462 20 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MK-462 40 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 1388093

Group type: EXPERIMENTAL
Intervention: Provera 500-mg tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Farlutal 500-mg tablet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Provera 500-mg granule packet
Number of subjects: 30
Study: 3916620

Group type: EXPERIMENTAL
Intervention: Computer-assisted meal-related insulin therapy (CAMIT = 3-4 injections daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy (CT = 2-3 injections daily)
Number of subjects: 12
Study: 31660706

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 160
Study: 29920214

Group type: EXPERIMENTAL
Intervention: T3 repletion (5 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (5 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Leptin repletion
Number of subjects: 9
Study: 27043753

Group type: EXPERIMENTAL
Intervention: Group B (content with hyperlinks to videos explaining key genetic concepts)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C (translated content with knowledge pearls embedded)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group A (control group with exact copy of text from MCG)
Number of subjects: 90
Study: 24089320

Group type: EXPERIMENTAL
Intervention: Health insurance-based case-management (trained account managers)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (untrained account managers)
Number of subjects: 100
Study: 23757762

Group type: EXPERIMENTAL
Intervention: Combined subthalamic nucleus and substantia nigra pars reticulata stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard subthalamic nucleus stimulation
Number of subjects: 12
Study: 20094040

Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 21
Study: 18545094

Group type: EXPERIMENTAL
Intervention: More intensive web-based stress management program
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Less intensive web-based stress management program
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 16507938

Group type: EXPERIMENTAL
Intervention: 100 microg levonorgestrel/20 microg ethinyl estradiol (20LNG group)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 100 microg levonorgestrel/30 microg ethinyl estradiol (30LNG group)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 1,000 microg norethindrone acetate/20 microg ethinyl estradiol (20NETA group)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 1,000 microg norethindrone acetate/30 microg ethinyl estradiol (30NETA group)
Number of subjects: 139
Study: 12581148

Group type: EXPERIMENTAL
Intervention: Nd‐Yag laser
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alexandrite laser
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 100
Study: 10949772

Group type: EXPERIMENTAL
Intervention: Evidence-based practice guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines dissemination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tools for implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Managed health care influences
Number of subjects: 0
Study: 7949691

Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) imaging at rest
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) imaging during active plantar flexion against resistance
Number of subjects: 24
Study: 2853441

Group type: EXPERIMENTAL
Intervention: 1% nedocromil sodium nasal spray given four times daily for four weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1% nedocromil sodium nasal spray
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30714388

Group type: COMPARATOR
Intervention: Visualization condition
Number of subjects: 47

Group type: COMPARATOR
Intervention: Combined Calendaring and Alarm condition
Number of subjects: 47

Group type: COMPARATOR
Intervention: Single session in-person intervention followed by tailored text messaging
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 47
Study: 27571889

Group type: EXPERIMENTAL
Intervention: Interactive web‐based sleep intervention based on cognitive behavioral therapy principles
Number of subjects: 30

Group type: COMPARATOR
Intervention: Web‐based education program
Number of subjects: 30
Study: 27419838

Group type: EXPERIMENTAL
Intervention: Adjustable sutures (AS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-adjustable sutures (NAS)
Number of subjects: 60
Study: 23312069

Group type: EXPERIMENTAL
Intervention: Grape seed extract powder (N31)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Green coffee caffeine powder (N677)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole coffee fruit concentrate powder (WCFC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Silica dioxide (placebo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10
Study: 21098819

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) reconstruction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single-bundle (SB) reconstruction
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (DB and SB)
Number of subjects: 53
Study: 18727151

Group type: EXPERIMENTAL
Intervention: Adenosine-induced hyperemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperemic conditions
Number of subjects: 0
Study: 17306313

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (DFEN) 45mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14761905

Group type: COMPARATOR
Intervention: General medicine trials
Number of subjects: 191

Group type: COMPARATOR
Intervention: Psychiatric trials
Number of subjects: 191

Group type: COMPARATOR
Intervention: Overall trials
Number of subjects: 191
Study: 11123730

Group type: EXPERIMENTAL
Intervention: Right main stem bronchial intubation (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low tidal volume-high frequency ventilation (Group B)
Number of subjects: 40
Study: 9023165

Group type: EXPERIMENTAL
Intervention: Oversizing at normal balloon pressures (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-pressure dilatation (group 2)
Number of subjects: 20
Study: 10188788

Group type: EXPERIMENTAL
Intervention: CI‐979/RU35926 (doses of 0.002-1.0 mg, with cholinergic symptoms observed at 2-4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CI‐979/RU35926
Number of subjects: 0
Study: 2115976

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 893719

Group type: EXPERIMENTAL
Intervention: Problem-solving training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Play-reading groups
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 29907079

Group type: EXPERIMENTAL
Intervention: Full navigation intervention
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Limited contact with navigators
Number of subjects: 1725

Group type: COMPARATOR
Intervention: No contact with navigators
Number of subjects: 1725
Study: 27839238

Group type: EXPERIMENTAL
Intervention: LEAF
Number of subjects: 10
Study: 25628469

Group type: EXPERIMENTAL
Intervention: Fit group (score = 0)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Intermediate fitness group (score = 1)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Frail group (score ≥2)
Number of subjects: 869
Study: 23649582

Group type: EXPERIMENTAL
Intervention: Visible light-cured (VLC) periodontal surgical dressing (Barricaid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylmethacrylate acrylic material (DuraLay Inlay Pattern Resin)
Number of subjects: 0
Study: 21565137

Group type: EXPERIMENTAL
Intervention: Xiaopi Yishen herbal extract granules (XPYS-HEG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 19030941

Group type: EXPERIMENTAL
Intervention: Moderately cross-linked polyethylene
Number of subjects: 48

Group type: COMPARATOR
Intervention: Historical polyethylene
Number of subjects: 48
Study: 16956475

Group type: EXPERIMENTAL
Intervention: 30 mg of ketorolac administered intravenously 30 minutes before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo administered intravenously 30 minutes before surgery
Number of subjects: 80
Study: 15286547

Group type: EXPERIMENTAL
Intervention: Immediate ultrasound
Number of subjects: 184

Group type: COMPARATOR
Intervention: Delayed ultrasound
Number of subjects: 184
Study: 10647527

Group type: EXPERIMENTAL
Intervention: Exercise (five 45-min brisk walking sessions per week at 75.2 +/- 0.5% of maximum heart rate)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 9028694

Group type: EXPERIMENTAL
Intervention: Levosulpiride (25 mg t.i.d. orally for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8122737

Group type: EXPERIMENTAL
Intervention: Detailed information group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine information group
Number of subjects: 40
Study: 3303693

Group type: EXPERIMENTAL
Intervention: Pharmaxolon treatment for 20 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control placebo group
Number of subjects: 34
Study: 29543566

Group type: EXPERIMENTAL
Intervention: Lapatinib (6 months) followed by trastuzumab (12 months)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Trastuzumab (12 months)
Number of subjects: 615
Study: 26952346

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 24961960

Group type: EXPERIMENTAL
Intervention: Air-Q intubating laryngeal airway
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flexible laryngeal mask airway
Number of subjects: 50
Study: 22832395

Group type: EXPERIMENTAL
Intervention: Intraoperative digital dilatation of the internal cervical ostium (group I)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No dilatation (group II)
Number of subjects: 94
Study: 19945340

Group type: EXPERIMENTAL
Intervention: EVT 201 1.5mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: EVT 201 2.5mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 18506387

Group type: EXPERIMENTAL
Intervention: Apomorphine (Apo) 7 microg/kg sc, administered in seven injections at 2-hour intervals
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (physiological saline), administered in seven injections at 2-hour intervals
Number of subjects: 18
Study: 15585311

Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stent
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 32
Study: 12856872

Group type: EXPERIMENTAL
Intervention: Qi-training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qi-therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study: 10774682

Group type: EXPERIMENTAL
Intervention: 300 mg oral artemether
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg intramuscular artemether
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg suppository artemether
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg oral artesunate (Guillin formulation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg oral artesunate (Arenco formulation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 mg oral dihydroartemisinin
Number of subjects: 8
Study: 8689881

Group type: EXPERIMENTAL
Intervention: EE-GTD (gestodene 75 micrograms + ethinylestradiol 30 micrograms)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EE-DSG (desogestrel 150 micrograms + ethinylestradiol 30 micrograms)
Number of subjects: 19

Group type: COMPARATOR
Intervention: EE-GTD and EE-DSG
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EE-DSG
Number of subjects: 19
Study: 1513957

Group type: EXPERIMENTAL
Intervention: 1-mile run/walk test
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: 1/2 mile run/walk test
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Criterion-referenced reliability (P, percent agreement)
Number of subjects: 1229
Study: 6603249

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate 500 mg every six hours for seven days
Number of subjects: 137

Group type: COMPARATOR
Intervention: Erythromycin or placebo preparation for a further week
Number of subjects: 137
Study: 30866943

Group type: COMPARATOR
Intervention: Placebo arm of a double-blind randomized vaccine trial
Number of subjects: 43
Study: 29341688

Group type: EXPERIMENTAL
Intervention: Randomized benchmarking (RB)
Number of subjects: 0
Study: 26912120

Group type: EXPERIMENTAL
Intervention: Board game
Number of subjects: 124

Group type: COMPARATOR
Intervention: Lecture-based seminar (Control)
Number of subjects: 124
Study: 25577869

Group type: EXPERIMENTAL
Intervention: Astaxanthin (25 mg x kg(‐1) x d(‐1) x bw(‐1)) from day 5 to 20 of pregnancy
Number of subjects: 30

Group type: COMPARATOR
Intervention: L-NAME (125 mg x kg(‐1) x d(‐1) x bw(‐1)) from days 10-20 of pregnancy
Number of subjects: 30
Study: 21295843

Group type: EXPERIMENTAL
Intervention: 7.5 mg PGF given 48 h prior to embryo collection (Treated cycle)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 7.5 mg PGF given at embryo collection (Control cycle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treated cycles
Number of subjects: 20
Study: 19387413

Group type: EXPERIMENTAL
Intervention: Experimental group (E): selected motion control, stability, or cushioned shoes based on plantar shape (n = 1,079 men and 451 women)
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Control group (C): received a stability shoe regardless of plantar shape (n = 1,068 men and 464 women)
Number of subjects: 2147
Study: 17686164

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: No adjuvant trastuzumab
Number of subjects: 0
Study: 15535485

Group type: EXPERIMENTAL
Intervention: Abdominal lavage with normal saline solution (3000 to 6000 ml)
Number of subjects: 21
Study: 11499536

Group type: EXPERIMENTAL
Intervention: PUVA (oral 8‐MOP plus UVA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PUVB (oral 8‐MOP plus UVB)
Number of subjects: 24
Study: 9694000

Group type: EXPERIMENTAL
Intervention: Alcoholics (mean MAO activity 0.34 pmol/hr/10(5) platelets, +/- 0.03)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls (mean MAO activity 0.27 pmol/hr/10(5) platelets, +/- 0.03)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Type 1 and Type 2 alcoholics
Number of subjects: 68
Study: 7946550

Group type: EXPERIMENTAL
Intervention: FM‐85
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EHMF
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prenan
Number of subjects: 24
Study: 3428346

Group type: EXPERIMENTAL
Intervention: muzolimine
Number of subjects: 0

Group type: COMPARATOR
Intervention: chlorthalidone
Number of subjects: 0
Study: 31949093

Group type: EXPERIMENTAL
Intervention: Acetazolamide + diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 115
Study: 30338584

Group type: COMPARATOR
Intervention: Older sexual minority men (OSMM)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Emerging adult sexual minority men (EA)
Number of subjects: 296
Study: 27899101

Group type: EXPERIMENTAL
Intervention: Participatory organizational-level intervention (25 months duration, including seminars, workshops, and workplace specific activities)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Participatory organizational-level intervention
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 664
Study: 24816689

Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 130

Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 130
Study: 22369958

Group type: EXPERIMENTAL
Intervention: Clay modeling (10 min constructing shapes from modeling clay)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clay modeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mental arithmetic task (counting backwards by threes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simpler verbal task (counting by ones)
Number of subjects: 0
Study: 20536477

Group type: EXPERIMENTAL
Intervention: Strip patch test
Number of subjects: 787

Group type: COMPARATOR
Intervention: Patch test
Number of subjects: 787
Study: 18396028

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) maneuver
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thixotropy conditioning of inspiratory muscles
Number of subjects: 16

Group type: COMPARATOR
Intervention: Without intervention (control)
Number of subjects: 16
Study: 15691561

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bimatoprost 0.03%
Number of subjects: 42
Study: 14523186

Group type: EXPERIMENTAL
Intervention: Care Ambassador (CA)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Care Ambassador plus psychoeducational modules (CA+)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard multidisciplinary diabetes care (SC)
Number of subjects: 299
Study: 11764108

Group type: EXPERIMENTAL
Intervention: Flowable RBC (AEeliteFlo, Revolution, UltraSeal XT, Flow-It)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hybrid RBC (control group)
Number of subjects: 50
Study: 8860097

Group type: EXPERIMENTAL
Intervention: Diuretics (95% thiazides and related agents) with high dietary sugar intake
Number of subjects: 2899

Group type: EXPERIMENTAL
Intervention: Diuretics (95% thiazides and related agents) with low dietary sugar intake
Number of subjects: 2899

Group type: COMPARATOR
Intervention: Other antihypertensive drugs
Number of subjects: 2899
Study: 1512524

Group type: EXPERIMENTAL
Intervention: Indobufen (400 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dipyridamole (225 mg/day) plus Acetylsalicylic Acid (1 g/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 6721524

Group type: EXPERIMENTAL
Intervention: Anthralin paste covered with semipermeable paper tape
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sites (symmetrical)
Number of subjects: 12
Study: 30803503

Group type: EXPERIMENTAL
Intervention: Freeze-dried bilberry (40 g/d) and standard medical therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group receiving standard medical therapy alone
Number of subjects: 50
Study: 30400984

Group type: EXPERIMENTAL
Intervention: Deep Dry Needling plus stretching
Number of subjects: 130

Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 130
Study: 25823387

Group type: EXPERIMENTAL
Intervention: Whole-grain bread (5 slices, 150g; 48% carbohydrates; 32% fat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Walnuts (56g; 8% carbohydrates; 84% fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher VAT (299 cm²) and higher BMI (32.4 kg/m²) in individuals with increased e-TEF response to bread compared to lower e-TEF response (VAT 223 cm², BMI 30.0 kg/m²); p = 0.024 and p = 0.013 respectively
Number of subjects: 40
Study: 25218720

Group type: EXPERIMENTAL
Intervention: Eating companion wearing overweight prosthesis (fatsuit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eating companion not wearing overweight prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating companion serving healthily (small amount of pasta, large amount of salad) with prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eating companion serving healthily (small amount of pasta, large amount of salad) without prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating companion serving unhealthily (large amount of pasta, small amount of salad) with prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eating companion serving unhealthily (large amount of pasta, small amount of salad) without prosthesis
Number of subjects: 0
Study: 22338863

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (AA group, n = 22)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amino acid and glucose infusion (AAGlu group, n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (AA group)
Number of subjects: 40
Study: 20207123

Group type: EXPERIMENTAL
Intervention: Formula with 130 mg DHA per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula with 0 mg DHA per day (control)
Number of subjects: 0
Study: 17221933

Group type: EXPERIMENTAL
Intervention: Secnidazole 500 mg oral dosage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference secnidazole tablets
Number of subjects: 20
Study: 15730173

Group type: EXPERIMENTAL
Intervention: 2.7-mm hysteroscope
Number of subjects: 371

Group type: COMPARATOR
Intervention: 4-mm hysteroscope
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 371